Giancarlo Castaman
University of Florence
435 Papers
3.6K Citations
Giancarlo Castaman is an academic researcher from University of Florence. The author has contributed to research in topics: Medicine & Von Willebrand disease. The author has an hindex of 60, co-authored 389 publications. Previous affiliations of Giancarlo Castaman include UniFi & University of Milan.
Chat about Author
Papers
Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors
Amy L. Dunn,Yesim Dargaud,Yasmina L. Abajas,Manuel Carcao,Giancarlo Castaman,Adam Giermasz,Cédric Hermans,Magdalena D. Lewandowska,Johnny Mahlangu,Shannon L. Meeks,Wolfgang Miesbach,Michael Recht,V. Salinas,Tammuella E Chrisentery-Singleton,Hongying Wang,Ian S. Mitchell,Guy Young +16 more
TL;DR: The PERSEPT 1 trial as mentioned in this paper was a prospective, randomized, crossover trial that investigated eptacog beta for the treatment of breakthrough bleeding episodes (BEs) in persons with hemophilia A or B with inhibitors in PwHABI (aged ≥12 years).
Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
Klaus Herbst,Johannes Oldenburg,T. M. Alvarez Román,Martin Sanabria,Giancarlo Castaman,Maissaa Janbain,Tadashi Matsushita,Karina Meijer,K. Schmidt,M. Reding +9 more
- 01 Feb 2023
TL;DR: In this paper , the safety results from the updated interim analysis were presented for Damoctocog alfa pegol (BAY 94-9027), a PEGylated, extended half-life recombinant factor VIII product, approved for treatment of previously treated patients aged ≥ 12 years with haemophilia A.
Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
Mark T. Reding,María Teresa Álvarez Román,Martin Sanabria,Giancarlo Castaman,Maissaa Janbain,Tadashi Matsushita,Karina Meijer,K. Schmidt,Johannes Oldenburg +8 more
TL;DR: In this paper , the safety and efficacy of extended dosing intervals were demonstrated with mild, moderate, or severe hemophilia in a pivotal PROTECT VIII studies (Reding et al, Haemophilia 2021).
Reply to: [Factor XI mutation and the origin of Ashkenazi Jews. Haematologica 2008; 93:e59]
Giorgia Zadra,Rosanna Asselta,Ml Tenchini,Giancarlo Castaman,Uri Seligsohn,P. M. Mannucci,Stefano Duga +6 more
TL;DR: It is unequivocally showed that the haplotype for factor XI type II mutation observed in Italians is identical with the founder haplotype discerned in Ashkenazi and Iraqi Jews as well as in Arabs.